ADCendo
Major Drugs - N/A, N/A, DK
ADCendo Details
ADCendo ApS seeks to explore novel targets in development of antibody-drug conjugates, to create new anti-cancer medicine for patients with a significant unmet need. The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen. The company is funded by a EUR 51M series a, completed in April 2021.ADCendo ApS is a resident company at Bioinnovation Institute (BII).
Website:
adcendo.dk
Employees:
10 - 19
HQ:
N/A
Location:
N/A, N/A, DK
Revenue:
1 - 2.5 Million
ADCendo Technologies
Retargeting
Facebook Custom Audiences
Email Providers
Outlook
CMS
WordPress.org
Fonts
Google Font API
SSL Certificates
Media Temple SSL
Other
Mobile Friendly